Outline of Consolidated Financial Results for the Year Ended March 31, 2014

May 13, 2014 NIPPON SHINYAKU CO., LTD.



Operating Results

	FY2012		FY2	013	YoY Change	
	Results	Ratio	Results	Ratio	Amt	%
Net sales	69,941	100.0%	76,517	100.0%	6,576	9.4%
Operating income	6,901	9.9%	8,038	10.5%	1,137	16.5%
Ordinary income	7,209	10.3%	8,598	11.2%	1,388	19.3%
Net income	4,647	6.6%	5,750	7.5%	1,102	23.7%



Segmental Review – Pharmaceuticals –

(Million yen)

	FY2012		FY2	013	YoY Change	
	Results	Ratio	Results	Ratio	Amt	%
Ethical drugs	57,344	98.3%	62,185	98.2%	4,840	8.4%
Revenues from the licensing of industrial property rights	104	0.2%	50	0.1%	-53	-51.6%
Prulifloxacin	664	1.1%	861	1.3%	196	29.5%
Contract manufacturing business	204	0.4%	248	0.4%	43	21.3%
Net sales	58,318	100.0%	63,345	100.0%	5,026	8.6%

etc.

Increase in sales:


- Vidaza (+2,676 Million yen, +38.1%) (Remedy for myelodysplastic sydrome)
- Lunabell (+1,589 Million yen, +34.3%) (Remedy for dysmenorrhea)
- Adcirca (+969 Million yen, +50.6%) (Remedy for pulmonary arterial hypertension)
- Tramal (+857 Million yen, +188.1%) (Remedy for cancer pain and chronic pain)

Decrease in sales:

- Livostin (-772 Million yen, -44.9%) (Remedy for allergic rhinitis and allergic conjunctivitis)
- Hypen (-446 Million yen, -13.4%) (Non-steroidal analgesic and anti-inflammatory agent)
- Erizas (-413 Million yen, -19.3%) (Remedy for allergic rhinitis)

etc.

Segmental Review – Pharmaceuticals –







Segmental Review — Functional Food —

	FY2012		FY2	013	YoY Change	
	Results	Ratio	Results	Ratio	Amt	%
Health food ingredients	886	7.6%	855	6.5%	-30	-3.5%
Preservatives	1,682	14.5%	1,764	13.4%	81	4.9%
Protein preparations	5,818	50.1%	7,126	54.1%	1,307	22.5%
Nutritional ingredients	1,818	15.6%	2,032	15.4%	213	11.8%
Others	1,416	12.2%	1,393	10.6%	-23	-1.6%
Net sales	11,622	100.0%	13,172	100.0%	1,549	13.3%

Segmental Review – Functional Food –



Net Sales





Consolidated Statements of Income

	FY2	FY2012		013	YoY C	hange
	Results	Ratio	Results	Ratio	Amt	%
Revenue						
Net sales	69,941	100.0%	76,517	100.0%	6,576	9.4%
Pharmaceuticals	58,318	83.4%	63,345	82.8%	5,026	8.6%
Functinal Food	11,622	16.6%	13,172	17.2%	1,549	13.3%
Operating expenses	63,040	90.1%	68,479	89.5%	5,438	8.6%
Cost of sales	34,776	49.7%	39,033	51.0%	4,257	
SG&A expenses	19,214	27.5%	19,914	26.0%	700	
R&D expenses	9,049	12.9%	9,530	12.5%	481	
Operating income	6,901	9.9%	8,038	10.5%	1,137	16.5%

(Million yen)

	FY2	012	FY2	013	YoY Change	
	Results	Ratio	Results	Ratio	Amt	%
Operating income	6,901	9.9%	8,038	10.5%	1,137	16.5%
Non-operating income	846	1.2%	1,019	1.3%	173	20.5%
Non-operating expenses	538	0.8%	460	0.6%	-78	-14.5%
Ordinary income	7,209	10.3%	8,598	11.2%	1,388	19.3%
Extraordinary profit	77	0.1%	-	-	-77	-
Income taxes	2,639	3.7%	2,847	3.7%	208	7.9%
Net income	4,647	6.6%	5,750	7.5%	1,102	23.7%

Dividends



		FY2012	FY2013
	Interim	¥10	¥11
Dividends per share	Year-end	¥11	¥12
	Annual	¥21	¥23
EPS		¥68.87	¥85.25
Dividends payout ratio		30.5 %	27.0 %
DOE		1.6 %	1.7 %



Consolidated Balance Sheet

	FY2012	FY2013	YoY Change		FY2012	FY2013	YoY Change
	4Q	4Q	Amt		4Q	4Q	Amt
Assets	113,730	118,188	4,458	Liabilities	24,201	25,002	801
(Current assets)	70,932	74,683	3,751	(Current liabilities)	15,677	15,257	-420
(Fixed assets)	42,798	43,504	706	(Long-term liabilities)	8,523	9,744	1,221
				Net assets	89,529	93,186	3,657
Total Assets	113,730	118,188	4,458	Total liabilities and net assets	113,730	118,188	4,458

(Million yen)

	FY2012	FY2013	YoY Change
	Results	Results	Amt
Operating activities	3,767	6,015	2,247
Investing activities	-2,026	-3,357	-1,330
Financing activities	-1,413	-1,606	-193
Cash and cash equivalents at end of year	20,044	21,229	1,185

Capital Investment

(Million yen)

	Results FY2012 FY2013 Amt Chg				
Capital investment	1,332	1,072	-259		
Depreciation	2,759	2,704	-55		

Breakdown of Capital Investment

NIPPON SHINYAKU CO., LTD.


	Results				
	FY2012	FY2013	Amt Chg		
<nippon co.,ltd.="" shinyaku=""></nippon>	1,182	1,017	-164		
Production	193	202	10		
R&D	532	661	129		
Others	457	153	-304		
<sioe co.,ltd.="" pharmaceutical=""></sioe>	49	22	-27		
<tajima co.,ltd.="" kogyo="" shokuhin=""></tajima>	101	32	-68		
Total capital investment	1,332	1,072	-259		



Business Forecast for FY2014

	FY20	13	FY20	14	YoY Change	
	Results	Ratio	Forecast	Ratio	Amt	%
Net sales	76,517	100.0%	84,000	100.0%	7,483	9.8%
Operating income	8,038	10.5%	8,500	10.1%	462	5.7%
Ordinary income	8,598	11.2%	8,700	10.4%	102	1.2%
Net income	5,750	7.5%	6,000	7.1%	250	4.3%

Segmental Forecast — Pharmaceuticals —





Segmental Forecast – Pharmaceuticals –

(Million yen)

	FY20	13	FY2014		YoY Change	
	Results	Ratio	Forecast	Ratio	Amt	%
Ethical drugs	62,185	98.2%	67,420	95.5%	5,235	8.4%
Revenues from the licensing of industrial property rights	50	0.1%	2,200	3.1%	2,150	4272.7%
Prulifloxacin	861	1.3%	800	1.1%	-61	- 7.1%
Contract manufacturing business	248	0.4%	180	0.3%	-68	- 27.5%
Net sales	63,345	100.0%	70,600	100.0%	7,255	11.5%

YoY change of new products (estimated)


•Vidaza (+11.4%)

•Lunabell (+7.8%)

•Zalutia (Launched in April 2014)

16

Segmental Forecast – Functional Food –





Segmental Forecast – Functional Food –

	FY20	13	FY20	14	YoY (Change
	Results	Ratio	Forecast	Ratio	Amt	%
Health food ingredients	855	6.5%	920	6.9%	65	7.6%
Preservatives	1,764	13.4%	1,800	13.4%	36	2.0%
Protein preparations	7,126	54.1%	7,200	53.7%	74	1.0%
Nutritional ingredients	2,032	15.4%	2,050	15.3%	18	0.8%
Others	1,393	10.6%	1,430	10.7%	37	2.7%
Net sales	13,172	100.0%	13,400	100.0%	228	1.7%



Consolidated Statements of Income (Forecast) (1)

	FY2013		FY2	014	YoY Change			
	Results	Ratio	Forecast	Ratio	Amt	%		
Revenue								
Net sales	76,517	100.0%	84,000	100.0%	7,483	9.8%		
Pharmaceuticals	63,345	82.8%	70,600	84.0%	7,255	11.5%		
Functinal Food	13,172	17.2%	13,400	16.0%	228	1.7%		
Operating expenses	68,479	89.5%	75,500	89.9%	7,021	10.3%		
Cost of sales	39,033	51.0%	43,100	51.3%	4,067			
SG&A expenses	19,914	26.0%	22,300	26.5%	2,386			
R&D expenses	9,530	12.5%	10,100	12.0%	570			
Operating income	8,038	10.5%	8,500	10.1%	462	5.7%		



	FY20	13	FY2014		YoY Change	
	Results	Ratio	Forecast	Ratio	Amt	%
Operating income	8,038	10.5%	8,500	10.1%	462	5.7%
Non-operating income	1,019	1.3%	700	0.8%	-319	- 31.3%
Non-operating expenses	460	0.6%	500	0.6%	40	8.7%
Ordinary income	8,598	11.2%	8,700	10.4%	102	1.2%
Income taxes	2,847	3.7%	2,700	3.2%	-147	- 5.2%
Net income	5,750	7.5%	6,000	7.1%	250	4.3%

Dividends Forecast



		FY2013	FY2014
	Interim	¥11	¥12
Dividends per share	Year-end	¥12	¥13
	Annual	¥23	¥25
EPS	¥85.25	¥88.98	
Dividends payout ratio	27.0 %	28.1 %	



Capital Investment Plan

(Million yen)

	FY2013 Results	FY2014 Forecast	Amt Chg
Capital investment	1,072	1,400	327
Depreciation	2,704	2,800	95

Breakdown of Capital investment

	FY2013 Results	FY2014 Forecast	Amt Chg
<nippon co.,ltd.="" shinyaku=""></nippon>	1,017	1,300	282
Production	202	480	277
R&D	661	620	-41
Others	153	200	46
<sioe co.,ltd.="" pharmaceutical=""></sioe>	22	40	17
<tajima co.,ltd.="" kogyo="" shokuhin=""></tajima>	32	60	27
Total capital investment	1,072	1,400	327

Status of Development Pipeline





R&D Pipeline (Domestic)

Code No. (Generic name) <origin></origin>	Application type	Indications	Stage	FY2012	FY2013	FY2014	FY2015
ACT-064992 (macitentan) <in-license></in-license>	NME	pulmonary arterial hypertension	Preparation for NDA	РШ 🛑		NDA Filing	
NS-24 (tramadol hydrochloride) <in-license></in-license>	new formulation	cancer pain chronic pain	Preparation for NDA	РⅢ		NDA Filing	
GA101 (obinutuzumab) <in-license></in-license>	NME	indolent non-Hodgkin's lymphoma aggressive non-Hodgkin's lymphoma	РШ	РШ			



R&D Pipeline (Domestic)

Code No. (Generic name) <origin></origin>	Application type	Indications	Stage	FY2012	FY2013	FY2014	FY2015
		pulmonary arterial hypertension	ΡI	ΡI			NDA Filing
NS-304 (selexipag)	NME	chronic thromboembolic	PI				
<in-house></in-house>	1 5	pulmonary hypertension		ΡI			
		arteriosclerosis obliterans	ΡI		РІ —		
NS-141		pruritus associated with					
<in-house></in-house>	NME	cutaneous disease	ΡI	ΡI			
NS-986 <in-license></in-license>	NME	nocturia	ΡI		PI		



R&D Pipeline (Overseas)

Code No. (Generic name) <origin></origin>	Application type	Indications	Stage	FY2012	FY2013	FY2014	FY2015
prulifloxacin <in-house></in-house>	NME	bacterial infections	China PⅢ	Lee's Pharr	na PII ——	ND Fili	
NS-304 (selexipag)		pulmonary arterial	US/EU	Actelion		NDA	
<in-house></in-house>		hypertension	РШ	РШ		Filing	
NS-187 (bafetinib)	NME	B-cell chronic lymphocytic	US	CytRx			
<in-house></in-house>		leukemia	ΡI	ΡI			
NS-018			US				
<in-house> NME myelofibrosis</in-house>	PI/PⅡ	PI/I					



ACT-064992 (Macitentan) - Treatment for PAH -

Development phase	 Overseas: Approval (2013, Europe and USA) Japan : Preparation for NDA 		
Origin	[Feb.2010] Licensed-in from: Actelion Pharmaceuticals Ltd.(Switzerland)		
Development	Co-development in Japan: Actelion Pharmaceuticals Japan Ltd.		
Indication	Pulmonary arterial hypertension		
Mechanism of action	Tissue-specific dual endothelin receptor antagonist		
Dosage form	Tablet		
Feature	 Less hepatic toxicity Long-acting oral drug 		



NS-24 (Tramadol) - Long-acting analgesic -

Development phase	Preparation for NDA
Origin	[Mar.2010] Licensed-in from: Paladin Labs Inc. (Canada) (available in 17 countries in the world)
Development	Nippon shinyaku
Indication	 Cancer pain Chronic pain
Dosage form	Sustained release tablet
Dosing regimen	Once a day
Feature	Long-acting analgesic with advantages of immediate release and sustained release



GA101 (Obinutuzumab) - Treatment for non-Hodgkin's lymphoma -

Develoment Phase	 Overseas: PIII (Multinational studies, Roche) Japan: PIII (Multinational studies) 			
Origin	[Nov. 2012] Licensed-in from: Chugai Pharmaceutical Co., Ltd.			
Development	Co-development in Japan: Chugai Pharmaceutical Co., Ltd.			
Indication	 Indolent non-Hodgkin's lymphoma Aggressive non-Hodgkin's lymphoma 			
Mechanism of action	Anti-CD20 monoclonal antibody			
Dosage form	Injection			
Feature	Anti-CD20 monoclonal antibody, increased antibody-dependent cellular cytotoxicity (ADCC) activity and direct cytotoxicity			

29



NS-304 (Selexipag)

- Treatment for pulmonary hypertension -

Development phase	Orphan drug designation by EMEA (Aug.2005) •Overseas : PIII •Japan : PII
Origin	•Nippon Shinyaku
Development	 [Apr. 2008] Licensed-out to (outside Japan): Actelion Pharmaceuticals Ltd.(Switzerland) Co-development in Japan: Actelion Pharmaceuticals Japan Ltd.
Indication	 Pulmonary hypertension Arteriosclerosis obliterans
Dosage form	Tablet
Mechanism of action	Selective PGI ₂ receptor agonist
Feature	Long-acting oral drug





Development phase	Additional PII (exploratory study)
Origin	Nippon Shinyaku
Development	Nippon Shinyaku
Indication	Pruritus associated with cutaneous disease
Dosage form	Ointment
Feature	 New mechanism of action (not antihistaminic) Effective against intractable pruritus which cannot be treated by existing treatments



NS-986 - Treatment for nocturia -

Development phase	PII (exploratory study)
Origin	[Mar.2013] Licensed-in from: Dainippon Sumitomo Pharma Co., Ltd.
Development	Nippon Shinyaku
Indication	Nocturia
Dosage form/ dosing regimen	Tablet / once a day
Mechanism of action	 Muscarinic receptor antagonist Na+ channel blocker
Feature	 Rapid onset of effect Improvement in nocturia refractory to existing antimuscarinic drugs

32



- Quinolone antibacterial -

Japan

Licensee	Development phase
 Meiji Seika Pharma Co., Ltd. 	 Launch (Dec. 2002) / Sword[®] Tablets

Overseas

Licensee	Development phase
 Angelini (Italy) 	 Approval (Sep. 2004) Launch in Italy (Nov. 2004) Approval in European countries (Apr. 2005)
 Lee's Pharmaceutical Holdings Ltd. (Hong Kong) 	• PIII (Jul. 2013)
 Algorithm (Lebanon) 	 Launch in Lebanon (Jan. 2012) Preparation for NDA in 11 countries of the Middle East and North Africa



NS-187(Bafetinib) - Tyrosine kinase inhibitor -

Development phase	Overseas: PII
Origin	Nippon Shinyaku
Development	[Dec. 2005] Licensed-out to (outside Japan): CytRx Corporation (USA)
Indication	B-cell chronic lymphocytic leukemia
Dosage form	Tablet
Mechanism of action	 Bcr-Abl tyrosine kinase inhibitor Lyn tyrosine kinase inhibitor
Feature	Dual tyrosine kinase inhibitor



NS-018 - Treatment for myelofibrosis -

Development Phase	Overseas (USA): PI/II
Origin	Nippon Shinyaku
Development	Nippon Shinyaku
Indication	Myelofibrosis
Dosage form	Tablet
Mechanism of action	JAK2 tyrosine kinase inhibitor
Feature	 Highly selective for active form of JAK2 tyrosine kinase Possibly best-in-class treatment for myelofibrosis



Safe Harbor Statement

- Materials and information provided during this presentation may contain so-called "forward-looking statements." These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could causeactual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion or failure of clinical trials; claims and concerns about product safety and efficacy; regulatory agency's examination, obtaining regulatory approvals; domestic and foreign social security reforms; trends toward healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- Also, for products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials, and competition with others.
- The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This English presentation was translated from the original Japanese version.
 In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.